Skip to content
Imexon
Imexon is a small molecule pharmaceutical. It is currently being investigated in clinical studies.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
8 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Non-small-cell lung carcinomaD002289112
Pancreatic neoplasmsD010190EFO_0003860C25112
MelanomaD008545111
B-cell chronic lymphocytic leukemiaD015451C91.111
Follicular lymphomaD008224C8211
Mantle-cell lymphomaD020522C83.111
Waldenstrom macroglobulinemiaD008258C88.011
Large b-cell lymphoma diffuseD016403C83.311
Burkitt lymphomaD002051C83.711
Multiple myelomaD009101C90.0111
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Prostatic neoplasmsD011471C6111
Breast neoplasmsD001943EFO_0003869C5011
Neoplasm metastasisD009362EFO_000970811
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameIMEXON
INNimexon
Description
Imexon (INN, trade name Amplimexon) is a substance that is being studied in the treatment of some types of cancer, including pancreatic, lung, breast, prostate, melanoma, and multiple myeloma. It is a cyanoaziridine derivative.
Classification
Small molecule
Drug class
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
N=C1NC(=O)N2CC12
Identifiers
PDB
CAS-ID59643-91-3
RxCUI
ChEMBL IDCHEMBL146428
ChEBI ID
PubChem CID68791
DrugBankDB05003
UNII ID8F63U28T2V (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 196 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
0 adverse events reported
View more details